CD8A and neoplasm: In keeping with this model, early studies showed that tumor editing represses antigen processing and presentation pathways and the expression of class I MHC to interfere with conventional TCR recognition, thus eliminating ‘signal 1’ for CD8+ T cell activation and its downstream antitumour effects (Khong and Restifo, 2002; Vesely et al, 2011).